Chimeric Antigen Receptor–Modified T Cells and T Cell–Engaging Bispecific Antibodies: Different Tools for the Same Job

PURPOSE OF REVIEW: Both chimeric antigen receptor (CAR) T cells and T cell–engaging antibodies (BiAb) have been approved for the treatment of hematological malignancies. However, despite targeting the same antigen, they represent very different classes of therapeutics, each with its distinct advanta...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwerdtfeger, Melanie, Benmebarek, Mohamed-Reda, Endres, Stefan, Subklewe, Marion, Desiderio, Vincenzo, Kobold, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
CART and immunotherapy (M Ruella and P Hanley, Section Editors)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154758/
https://www.ncbi.nlm.nih.gov/pubmed/33939108
http://dx.doi.org/10.1007/s11899-021-00628-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154758/
https://www.ncbi.nlm.nih.gov/pubmed/33939108
http://dx.doi.org/10.1007/s11899-021-00628-2

Ejemplares similares